...
首页> 外文期刊>Journal of endovascular therapy: an official journal of the International Society of Endovascular Specialists >Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial.
【24h】

Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial.

机译:重组组织纤溶酶原激活物与尿激酶对股pop闭塞的局部溶栓作用:一项前瞻性,随机,多中心试验。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: To report the outcome of a prospective, randomized, open multicenter trial comparing (1) the effects of local thrombolysis with recombinant tissue plasminogen activator (rtPA) or urokinase (UK) and (2) 2 administration techniques. METHODS: Two hundred thirty-four patients with thromboembolic occlusions in 223 native femoral or popliteal arteries (95%) and 11 bypass grafts (5%) were randomized to rtPA (n = 124) or UK (n = 110) administered either through an endhole catheter (Hess technique) in 81 patients or a microporous balloon catheter (Schneider technique) in 153 patients. When lysis was incomplete, additional catheter interventions were applied to achieve patency. Results were analyzed by fluoroscopy during intervention and by angiography evaluated by independent experts blinded to the methods applied. RESULTS: The only significant difference between rtPA and UK was found at the end of lysis using the Hess technique. Complete reperfusion (TIMI grade 3) was produced in 60% of patients by rtPA versus 37% by UK (p = 0.045). By both techniques TIMI grade 3 was achieved in 62% with rtPA and in 50% with UK (p = 0.18). Independent of delivery technique, thrombolytic agent, or additional catheter interventions, TIMI grade 3 was achieved in 81% and angiographic patency in 88%. Primary patency at 6 months was 66%, which was increased by secondary interventions to 75%. Major amputations were performed in 6%, all in patients with initial Fontaine stage III/IV ischemia. CONCLUSIONS: With local thrombolysis alone, rtPA appears to be more effective than UK; however, additional catheter interventions further improved patency, abolishing the difference between the lytic agents.
机译:目的:报告一项前瞻性,随机,开放的多中心试验的结果,该试验比较(1)重组组织纤溶酶原激活剂(rtPA)或尿激酶(UK)对局部溶栓的影响以及(2)2种给药技术。方法:将223例股或pop动脉(95%)和11例旁路移植(5%)的234例血栓栓塞患者随机分配至rtPA(n = 124)或UK(n = 110)或通过内窥镜导管(Hess技术)81例,微孔球囊导管(Schneider技术)153例。当溶胞不完全时,需进行额外的导管干预以达到通畅。在干预期间通过荧光检查分析结果,并由不了解所应用方法的独立专家对血管造影术进行评估。结果:使用Hess技术在裂解结束时发现rtPA和UK之间唯一的显着差异。 rtPA产生了60%的患者完全再灌注(TIMI 3级),而UK产生了37%(p = 0.045)。通过这两种技术,使用rtPA达到TIMI 3级(62%),使用UK达到50%(p = 0.18)。与输送技术,溶栓剂或其他导管干预措施无关,TIMI 3级达到81%,血管造影通畅率为88%。 6个月时的主要通畅率为66%,通过二次干预增加到75%。在最初的Fontaine III / IV期局部缺血的患者中,有6%的患者进行了大面积截肢。结论:仅使用局部溶栓治疗,rtPA似乎比英国更有效。然而,额外的导管干预进一步改善了通畅性,消除了裂解剂之间的差异。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号